Peter Kluge, DO
Interventional Cardiology · Eau Claire, WINPI 1861613523
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,298 of the $4,995 with a category attached, or 66.0%. 6 manufacturers reported payments, led by Edwards Lifesciences at 53.2% of the total. Reporting peaked in 2019 at $2,696 and has fallen 98.8% since, to $33 in 2025.
Across 75 payments — averaging $66.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$3K
- Abbott$2K
- Medtronic$110
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$57
- Boston Scientific$33
- Biotronik Inc.$15
What the payments were for
- Travel & lodging$3,29866%
- Food & beverage$1,68234%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 33 | $2,655 |
| Abbott | 35 | $2,125 |
| Medtronic | 2 | $110 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $57 |
| Boston Scientific | 1 | $33 |
| Biotronik Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$2,273
- Fortify Assura$1,247
- GALLANT$103
How this compares
$4,995 in reported general payments places this provider in the 60th percentile of 118 interventional cardiology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 162 | $177,142 |
| XareltoRivaroxaban | 66 | $57,516 |
| JardianceEmpagliflozin | 54 | $47,132 |
| EntrestoSacubitril/Valsartan | 14 | $19,224 |
| MultaqDronedarone Hcl | 14 | $17,322 |
| Dofetilide | 14 | $2,642 |
| Metoprolol Succinate | 154 | $2,198 |
| Ezetimibe | 82 | $1,730 |
| Losartan Potassium | 135 | $1,469 |
| ClopidogrelClopidogrel Bisulfate | 126 | $1,458 |
| Atorvastatin Calcium | 112 | $901 |
| Spironolactone | 116 | $890 |
| Lisinopril | 57 | $749 |
| Rosuvastatin Calcium | 55 | $674 |
| Amiodarone Hcl | 29 | $667 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Eau Claire
- Emad DodinEau Claire$5K
- Michael SalingerMilwaukee$216K
- Arun KalyanasundaramMarshfield$201K
- Michael RosenbergManitowoc$111K
- Tanvir BajwaMilwaukee$106K
- Suhail AllaqabandMilwaukee$88K
- Saif AnwaruddinMilwaukee$80K
- Raaid MuseitifKenosha$71K
- Iyad AzzamMilwaukee$60K
- Mark HoffmannWausau$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.